Overview

A Randomized Phase II Efficacy, Activity and Safety Study of GLQ223 Alone and in Combination With Zidovudine in Symptomatic HIV-Infected Patients Without Prior Treatment With GLQ223 or Trichosanthin

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This study involves GLQ223 administration to patients who have not previously been exposed to it, but who have received at least 9 months of zidovudine therapy. Efficacy evaluations will include survival, opportunistic infections, T4 cell count, and assessments of viral load.

Phase:

Phase 2

Details

Lead Sponsor:

Genelabs Technologies

Treatments:

Trichosanthin
Zidovudine